Alteration of Gut Microbiota in Inflammatory Bowel Disease (IBD): Cause or Consequence? IBD Treatment Targeting the Gut Microbiome
Open accessThe DOI matches its Crossref record; 267 of the 267 references it cites were found in a registry or an index.
Abstract
Inflammatory bowel disease (IBD) is a chronic complex inflammatory gut pathological condition, examples of which include Crohn’s disease (CD) and ulcerative colitis (UC), which is associated with significant morbidity. Although the etiology of IBD is unknown, gut microbiota alteration (dysbiosis) is considered a novel factor involved in the pathogenesis of IBD. The gut microbiota acts as a metabolic organ and contributes to human health by performing various physiological functions; deviation in the gut flora composition is involved in various disease pathologies, including IBD. This review aims to summarize the current knowledge of gut microbiota alteration in IBD and how this contributes to intestinal inflammation, as well as explore the potential role of gut microbiota-based treatment approaches for the prevention and treatment of IBD. The current literature has clearly demonstrated a perturbation of the gut microbiota in IBD patients and mice colitis models, but a clear causal link of cause and effect has not yet been presented. In addition, gut microbiota-based therapeutic approaches have also shown good evidence of their effects in the amelioration of colitis in animal models (mice) and IBD patients, which indicates that gut flora might be a new promising therapeutic target for the treatment of IBD. However, insufficient data and confusing results from previous studies have led to a failure to define a core microbiome associated with IBD and the hidden mechanism of pathogenesis, which suggests that well-designed randomized control trials and mouse models are required for further research. In addition, a better understanding of this ecosystem will also determine the role of prebiotics and probiotics as therapeutic agents in the management of IBD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Alterations in sex hormones levels may lead to microbial dysbiosis which has been previously implicated in IBD and its symptom severity.(40)”
From Association Between Sex Hormone Levels and Gut Microbiota Composition and Diversity—A Systematic Review (2022) · cites this paper as [40]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A human gut microbial gene catalogue established by metagenomic sequencing
MetaHIT Consortium, Qin, J., Li, R., Raes, J., Arumugam, M., Burgdorf, K. S., Manichanh, C., Nielsen, T., Pons, N., Levenez, F., et al. (2010) · Nature · doi:10.1038/nature08821 · Cited by 11,624 · cited 3×
“25% (fewer) of the mucosal microbial genes of healthy individuals [25].”
BackgroundInfluentialChanges of Intestinal Functions in Liver Cirrhosis
Fukui, H., & Wiest, R. (2016) · Inflammatory Intestinal Diseases · doi:10.1159/000444436 · Cited by 6,808
Ng, S. C., Shi, H. Y., Hamidi, N., Underwood, F. E., Tang, W., Benchimol, E. I., Panaccione, R., Ghosh, S., Wu, J. C. Y., Chan, F. K. L., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32448-0 · Cited by 6,087 · cited 1×
“The highest incidence rate has been recorded in developed countries, such as North America, Europe, Australia, and New Zealand [6], while recently, IBD has been gradually becoming more common in developing areas such as Asia and South America, and in developing countries such as including Brazil, South Korea, and Chin…”
BackgroundAssociation of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease
Hugot, J.-P., Chamaillard, M., Zouali, H., Lesage, S., Cézard, J.-P., Belaiche, J., Almer, S., Tysk, C., O'Morain, C. A., Gassull, M., et al. (2001) · Nature · doi:10.1038/35079107 · Cited by 5,591 · cited 2×
“The NOD2 (nucleotide-binding oligomerization domain containing protein 2), a first gene locus, has been reported as a risk locus for Crohn’s disease (CD) [175,176].”
BackgroundDe Filippo, C., Cavalieri, D., Di Paola, M., Ramazzotti, M., Poullet, J. B., Massart, S., Collini, S., Pieraccini, G., & Lionetti, P. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1005963107 · Cited by 5,579 · cited 1×
“Human Bacteroidetes Firmicutes, Enterobacteriaceae Decrease Increase [163]”
A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease
Ogura, Y., Bonen, D. K., Inohara, N., Nicolae, D. L., Chen, F. F., Ramos, R., Britton, H., Moran, T., Karaliuskas, R., Duerr, R. H., et al. (2001) · Nature · doi:10.1038/35079114 · Cited by 5,030 · cited 1×
“The NOD2 (nucleotide-binding oligomerization domain containing protein 2), a first gene locus, has been reported as a risk locus for Crohn’s disease (CD) [175,176].”
BackgroundDiarrheagenic Escherichia coli
Nataro, J. P., & Kaper, J. B. (1998) · Clinical Microbiology Reviews · doi:10.1128/cmr.11.1.142 · Cited by 5,006 · cited 1×
“Many studies in human IBD patients have reported the commensal bacteria association with the patient’s intestines; for example, an association of adherent/invasive Escherichia coli (AIEC), a normal gut flora of the Enterobacteriaceae group, has been found with CD [121].”
BackgroundMetabolites produced by commensal bacteria promote peripheral regulatory T-cell generation
Arpaia, N., Campbell, C., Fan, X., Dikiy, S., van der Veeken, J., deRoos, P., Liu, H., Cross, J. R., Pfeffer, K., Coffer, P. J., et al. (2013) · Nature · doi:10.1038/nature12726 · Cited by 4,838 · cited 1×
“In addition, certain symbiotic gut microbiota members have been reported to have distinct and specific effects on the host immune system, and are considered key to immune homeostasis [31,37,38].”
BackgroundHost–microbe interactions have shaped the genetic architecture of inflammatory bowel disease
The International IBD Genetics Consortium (IIBDGC), Jostins, L., Ripke, S., Weersma, R. K., Duerr, R. H., McGovern, D. P., Hui, K. Y., Lee, J. C., Philip Schumm, L., Sharma, Y., et al. (2012) · Nature · doi:10.1038/nature11582 · Cited by 4,722 · cited 1×
“Genome-wide association studies (GWAS) have identified more than 160 genetic loci associated with conferring protection from IBD or increased risk to IBD development [172].”
BackgroundRichness of human gut microbiome correlates with metabolic markers
Le Chatelier, E., Nielsen, T., Qin, J., Prifti, E., Hildebrand, F., Falony, G., Almeida, M., Arumugam, M., Batto, J.-M., Kennedy, S., et al. (2013) · Nature · doi:10.1038/nature12506 · Cited by 4,662
Research works printed but not linked: 2
- Zhang, 2007, Wumei pill decoction in the treatment of 72 cases of chronic nonspecific ulcerative colitis, Mod. J. Integr. Tradit. West. Med., 16, 5156
- Yan, 2013, Effect of Astragalus Polysaccharides on Th17/Treg Cytokines and Pulmonary Inflammation in Asthmatic Rats, Chin. Pharmacol. Bull., 29, 1275
Cited by
Items 101–200 of 804
Gut Microbiota Serves as a Crucial Independent Biomarker in Inflammatory Bowel Disease (IBD)
Sharma, B., Agriantonis, G., Twelker, K., Ebelle, D., Kiernan, S., Siddiqui, M., Soni, A., Cheerasarn, S., Simon, W., Jiang, W., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26062503 · Cited by 64
“Since PDPN expression is known to be upregulated in inflamed tissues, the altered microbiota can indirectly affect PDPN levels by promoting inflammation [82,83].”
The canine gastrointestinal microbiota: early studies and research frontiers
Huang, Z., Pan, Z., Yang, R., Bi, Y., & Xiong, X. (2020) · Gut Microbes · doi:10.1080/19490976.2019.1704142 · Cited by 69
Hanscom, M., Loane, D. J., Aubretch, T., Leser, J. M., Molesworth, K., Hedgekar, N., Ritzel, R. M., Abulwerdi, G. A., Shea‐Donohue, T., & Faden, A. I. (2021) · Journal of Neuroinflammation · doi:10.1186/s12974-020-02067-x · Cited by 67
Hu, W., Gong, W., Yang, F., Cheng, R., Zhang, G., Gan, L., Zhu, Y., Qin, W., Gao, Y., Li, X., et al. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113937 · Cited by 63
Kang, G.-U., Jung, D.-R., Lee, Y. H., Jeon, S. Y., Han, H. S., Chong, G. O., & Shin, J. (2021) · Microorganisms · doi:10.3390/microorganisms9020294 · Cited by 62
Jang, H., Kim, J.-K., Joo, M.-K., Shin, Y.-J., Lee, K., Lee, C. K., Kim, H. J., & Kim, D. (2022) · Scientific Reports · doi:10.1038/s41598-022-13629-9 · Cited by 63
Battaglia, M. C., & Garrett‐Sinha, L. A. (2020) · Journal of Translational Autoimmunity · doi:10.1016/j.jtauto.2020.100078 · Cited by 66
“Bacterial dysbiosis been welldocumented in inflammatory diseases such as inflammatory bowel disease and ulcerative colitis [52,53].”
BackgroundSharma, S., Bhatia, R., Devi, K., Rawat, A., Singh, S., Bhadada, S. K., Bishnoi, M., Sharma, S. S., & Kondepudi, K. K. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.123326 · Cited by 60
Sheng, Q., Li, F., Chen, G., Li, J., Li, J., Wang, Y., Lu, Y., Li, Q., Li, M., & Chai, K. (2021) · Journal of Immunology Research · doi:10.1155/2021/6679316 · Cited by 59
“The character of UC is intestinal immune imbalance and intestinal microbial disorder [23, 24].”
BackgroundDarb Emamie, A., Rajabpour, M., Ghanavati, R., Asadolahi, P., Farzi, S., Sobouti, B., & Darbandi, A. (2021) · Journal of Applied Microbiology · doi:10.1111/jam.14907 · Cited by 57
“In recent years, the interest in microbiota-based IBD therapy has gained more popularity, due in part to having fewer adverse effects than traditional therapies (Khan et al.2019).”
BackgroundThe role of gut microbiome in inflammatory bowel disease diagnosis and prognosis
Zheng, J., Sun, Q., Zhang, J., & Ng, S. C. (2022) · United European Gastroenterology Journal · doi:10.1002/ueg2.12338 · Cited by 60
Modulatory Effect of Gut Microbiota on the Gut-Brain, Gut-Bone Axes, and the Impact of Cannabinoids
Ibrahim, I., Soumyakrishnan, S., Ayariga, J. A., Xu, J., Robertson, B. K., SREEPRIYA, M., & Ajayi, O. S. (2022) · Metabolites · doi:10.3390/metabo12121247 · Cited by 61
The Neglected Gut Microbiome: Fungi, Protozoa, and Bacteriophages in Inflammatory Bowel Disease
Guzzo, G. L., Andrews, J. M., & Weyrich, L. S. (2022) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izab343 · Cited by 59
Bamola, V. D., Dubey, D., Samanta, P., Kedia, S., Ahuja, V., Madempudi, R. S., Neelamraju, J., & Chaudhry, R. (2022) · Anaerobe · doi:10.1016/j.anaerobe.2022.102652 · Cited by 64
Beneficial Bacteria Isolated from Food in Relation to the Next Generation of Probiotics
Sionek, B., Szydłowska, A., Zielińska, D., Neffe‐Skocińska, K., & Kołożyn‐Krajewska, D. (2023) · Microorganisms · doi:10.3390/microorganisms11071714 · Cited by 62
Pietrucci, D., Teofani, A., Milanesi, M., Fosso, B., Putignani, L., Messina, F., Pesole, G., Desideri, A., & Chillemi, G. (2022) · Biomedicines · doi:10.3390/biomedicines10082028 · Cited by 63
Beneficial effects of seaweed-derived components on metabolic syndrome via gut microbiota modulation
Zang, L., Baharlooeian, M., Terasawa, M., Shimada, Y., & Nishimura, N. (2023) · Frontiers in Nutrition · doi:10.3389/fnut.2023.1173225 · Cited by 59
Animal models of inflammatory bowel disease: category and evaluation indexes
Wen, C., Chen, D., Zhong, R., & Peng, X. (2023) · Gastroenterology report · doi:10.1093/gastro/goae021 · Cited by 64
Pharmacological effects of ginseng and ginsenosides on intestinal inflammation and the immune system
Zhao, L., Zhang, T., & Zhang, K. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1353614 · Cited by 75
Gu, Z., Zhu, Y., Jiang, S., Xia, G., Li, C., Zhang, X., Zhang, J., & Shen, X. (2020) · Food & Function · doi:10.1039/d0fo00116c · Cited by 55
Intensive, prolonged exercise seemingly causes gut dysbiosis in female endurance runners
Morishima, S., Aoi, W., Kawamura, A., Kawase, T., Takagi, T., Naito, Y., Tsukahara, T., & Inoue, R. (2021) · Journal of Clinical Biochemistry and Nutrition · doi:10.3164/jcbn.20-131 · Cited by 48
Native and Engineered Probiotics: Promising Agents against Related Systemic and Intestinal Diseases
Shen, H., Zhao, Z., Zhao, Z., Chen, Y., & Zhang, L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23020594 · Cited by 58
Oral Delivery of Biologics in Inflammatory Bowel Disease Treatment
Zhang, W., Michalowski, C. B., & Beloqui, A. (2021) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2021.675194 · Cited by 63
Choudhary, N., Dhingra, N., Gacem, A., Yadav, V. K., Verma, R. K., Choudhary, M., Bhardwaj, U., Chundawat, R. S., Alqahtani, M. S., Gaur, R. K., et al. (2023) · Frontiers in Plant Science · doi:10.3389/fpls.2023.1193573 · Cited by 54
Gut Microbiome as a Target of Intervention in Inflammatory Bowel Disease Pathogenesis and Therapy
Hetta, H. F., Ramadan, Y. N., Alharbi, A. A., Alsharif, S. M., Alkindy, T. T., Alkhamali, A., Albalawi, A. S., & El‐Amin, H. (2024) · Immuno · doi:10.3390/immuno4040026 · Cited by 57
“Several parts of the intestine have various communities, beginning in the duodenum with aerobic Lactobacillus and Streptococcus spp. and ending towards the colon with strong anaerobic organisms like Bifidobacterium , Bacteroides , and clostridial clusters [57].”
BackgroundInfluentialZeng, W., He, D., Xing, Y., Liu, J., Su, N., Zhang, C., Wang, Y., & Xing, X. (2021) · Food Science and Human Wellness · doi:10.1016/j.fshw.2021.02.016 · Cited by 55
Self-citationLi, J. V., Ashrafian, H., Sarafian, M. H., Homola, D., Rushton, L., Barker, G. F., Cabrera, P. M., Lewis, M. R., Darzi, A. W., Lin, E., et al. (2021) · Microbiome · doi:10.1186/s40168-021-01086-x · Cited by 60
Thinned peach polyphenols alleviate obesity in high fat mice by affecting gut microbiota
Dai, K., Song, Y., Zhang, D., Wei, Y., Jiang, S., Xu, F., Wang, H., Zhang, X., & Shao, X. (2022) · Food Research International · doi:10.1016/j.foodres.2022.111255 · Cited by 53
Role of Microbiota in Viral Infections and Pathological Progression
Mizutani, T., Ishizaka, A., Koga, M., Tsutsumi, T., & Yotsuyanagi, H. (2022) · Viruses · doi:10.3390/v14050950 · Cited by 59
Naseri, K., Saadati, S., Yari, Z., Asbaghi, O., Hezaveh, Z. S., Mafi, D., Hoseinian, P., Ashtary‐Larky, D., Hekmatdoost, A., & de Courten, B. V. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106288 · Cited by 59
Xu, N., Bai, X., Cao, X., Yue, W., Jiang, W., & Yu, Z. (2020) · Microbial Pathogenesis · doi:10.1016/j.micpath.2020.104707 · Cited by 57
Yang, M., Yang, C., Zhang, Y., Yan, X., Ma, Y., Zhang, Y., Cao, Y., Xu, Q., Tu, K., & Zhang, M. (2021) · Biomaterials Science · doi:10.1039/d1bm01765a · Cited by 55
Deleterious Effect of Air Pollution on Human Microbial Community and Bacterial Flora: A Short Review
Gupta, N., Yadav, V. K., Gacem, A., Al-Dossari, M., Yadav, K. K., El-Gawaad, N. S. A., Khedher, N. B., Choudhary, N., Kumar, P., & Cavalu, S. D. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph192315494 · Cited by 55
Microbial pathogenesis in inflammatory bowel diseases
Kumar, S., & Kumar, A. (2021) · Microbial Pathogenesis · doi:10.1016/j.micpath.2021.105383 · Cited by 53
Xinzhou, W., Liu, Y., Wu, Z., Zhang, P., & Zhang, X. (2022) · Antioxidants · doi:10.3390/antiox11020253 · Cited by 55
Abdominal Pain in Inflammatory Bowel Diseases: A Clinical Challenge
Wils, P., Caron, B., D’Amico, F., Danese, S., & Peyrin‐Biroulet, L. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11154269 · Cited by 56
Kurhaluk, N., Kamiński, P., Bilski, R., Kołodziejska, R., Woźniak, A., & Ткаченко, Г. М. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26083658 · Cited by 58
“Such conditions as irritable bowel syndrome (IBS), functional dyspepsia, and IBD are often associated with microbial dysregulation, but it remains unclear whether dysbiosis is a consequence or a driver of chronic inflammation [163].”
Caviglia, G. P., Rosso, C., Stalla, F., Rizzo, M., Massano, A., Abate, M. L., Olivero, A., Armandi, A., Vanni, E., Younes, R., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9030800 · Cited by 50
Kaltsas, A., Zachariou, A., Markou, E., Dimitriadis, F., Sofikitis, N., & Pournaras, S. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13101491 · Cited by 53
Hayat, M. F., Zohaib, M., Ijaz, M. U., Batool, M., Ashraf, A., Almutairi, B. O., & Atique, U. (2024) · Journal of Trace Elements in Medicine and Biology · doi:10.1016/j.jtemb.2024.127445 · Cited by 55
Marvi-Khorasani, H., Usefi, H., & Peña‐Castillo, L. (2020) · Scientific Reports · doi:10.1038/s41598-020-70583-0 · Cited by 55
Wang, Y., Zhang, J., Xu, L., Ma, J., Lu, M., Ma, J., Liu, Z., Wang, F., & Tang, X. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.756978 · Cited by 60
The role of retinoic acid in the production of immunoglobulin A
Bos, A. V., van Egmond, M., & Mebius, R. E. (2022) · Mucosal Immunology · doi:10.1038/s41385-022-00509-8 · Cited by 54
Microbial‐derived indoles inhibit neutrophil myeloperoxidase to diminish bystander tissue damage
Alexeev, E. E., Dowdell, A. S., Henen, M. A., Lanis, J. M., Lee, J. S., Cartwright, I. M., Schaefer, R. E. M., Ornelas, A., Onyiah, J. C., Vögeli, B., et al. (2021) · The FASEB Journal · doi:10.1096/fj.202100027r · Cited by 49
Garavaglia, B., Vallino, L., Amoruso, A., Pane, M., Ferraresi, A., & Isidoro, C. (2024) · Aspects of Molecular Medicine · doi:10.1016/j.amolm.2024.100056 · Cited by 51
The Microbiome in Health and Disease from the Perspective of Modern Medicine and Ayurveda
Wallace, R. K. (2020) · Medicina · doi:10.3390/medicina56090462 · Cited by 51
Peñalva, R., Martínez‐López, A. L., Gamazo, C., González-Navarro, C. J., González-Ferrero, C., Virto, R., Brotons-Canto, A., Vitas, A. I., Collantes, M., Peñuelas, I., et al. (2022) · Food Hydrocolloids · doi:10.1016/j.foodhyd.2022.108213 · Cited by 47
“…can contribute to the development of a variety of health complications, including inflammatory bowel disease and irritable bowel syndrome (Khan et al., 2019; Simon, C ˘ alinoiu, Mitrea, & Vodnar, 2021), as well as to worsen particular manifestations of some diseases such as obesity, type…”
BackgroundThromboembolic Events in Patients with Inflammatory Bowel Disease: A Comprehensive Overview
Gala, D., Newsome, T., Roberson, N., Lee, S. M., Thekkanal, M., Shah, M., Kumar, V., Bandaru, P. K. R., & Gayam, V. B. R. (2022) · Diseases · doi:10.3390/diseases10040073 · Cited by 47
Cerdó, T., García-Santos, J. A., Rodríguez-Pöhnlein, A., García-Ricobaraza, M., Nieto-Ruíz, A., García-Bermúdez, M., & Campoy, C. (2022) · Nutrients · doi:10.3390/nu14214691 · Cited by 51
Functional and Therapeutic Potential of Cynara scolymus in Health Benefits
Porro, C., Benameur, T., Cianciulli, A., Vacca, M., Chiarini, M., Angelis, M. D., & Panaro, M. A. (2024) · Nutrients · doi:10.3390/nu16060872 · Cited by 55
Smith, B. J., Piceno, Y. M., Zydek, M., Zhang, B., Syriani, L. A., Terdiman, J. P., Kassam, Z., Ma, A. I., Lynch, S. V., Pollard, K. S., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-09307-5 · Cited by 50
“In addition, the role of the gut microbiome in the etiology of UC is unsettled; the composition of the gut microbiome is known to differ in UC cases compared to healthy controls but it remains unclear if these differences are a major cause of the disease or a result of underlying inflammation [11,12].”
BackgroundAmeba-inspired strategy enhances probiotic efficacy via prebound nutrient supply
Pan, C., Jiang, X., Wei, J., Liu, C., Zhang, M., Gao, C., Chen, R., Yang, C., Wang, B., Yu, M., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-57071-7 · Cited by 48
Rodríguez‐García, C., Sánchez‐Quesada, C., Algarra, I., & Gaforio, J. J. (2020) · Nutrients · doi:10.3390/nu12061705 · Cited by 46
Zhang, F., Ferrero, M., Dong, N., D’Auria, G., Reyes-Prieto, M., Herreros-Pomares, A., Calabuig-Fariñas, S., Duréndez, E., Aparisi, F., Blasco, A., et al. (2021) · Cancers · doi:10.3390/cancers13112514 · Cited by 43
Spiller, A. L., da Costa, B. G., Yoshihara, R. N. Y., Nogueira, E. J. Z., Castelhano, N. S., Santos, A., de Freitas, M. B., Magro, D. O., & Sassaki, L. Y. (2025) · Nutrients · doi:10.3390/nu17162677 · Cited by 52
“A disrupted microbiota in IBD is associated with elevated proinflammatory cytokines (including TNF-α and IL-6) and the activation of inflammatory signaling pathways like nuclear factor kappa B (NF-κ B), contributing to sustained gastrointestinal inflammation [114].”
Wang, Y., Zhou, Y., Wu, Q., Li, Y., Huang, Y., Yu, K., Li, P., Lv, Z., Liu, H., Zou, H., et al. (2025) · Advanced Science · doi:10.1002/advs.202505208 · Cited by 58
Salinas, E., Reyes-Pavón, D., Cortes‐Perez, N. G., Torres-Maravilla, E., Bitzer-Quintero, O. K., Langella, P., & Bermúdez‐Humarán, L. G. (2021) · Microorganisms · doi:10.3390/microorganisms9081634 · Cited by 48
Xu, P., Luo, S., Song, J., Dai, Z., Li, D., & Wu, C. (2023) · Food Science and Human Wellness · doi:10.1016/j.fshw.2023.03.010 · Cited by 44
Li, M., Wu, Y.-Z., Jian-guo, Q., Lei, J.-X., Li, M., Xu, N., Liu, Y., Jin, Z., Su, Z., Lee, S. M., et al. (2023) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2023.116430 · Cited by 45
Zeng, Z., Xie, Z., Chen, G., Sun, Y., Zeng, X., & Liu, Z. (2021) · Food & Function · doi:10.1039/d1fo02702f · Cited by 43
Chen, Y., Rudolph, S., Longo, B. N., de Pace, F., Roh, T. T., Condruti, R., Gee, M. M., Watnick, P. I., & Kaplan, D. L. (2022) · Advanced Healthcare Materials · doi:10.1002/adhm.202200447 · Cited by 43
Impact of gut Microbiome alteration in Ulcerative Colitis patients on disease severity and outcome
Basha, O. M., Hafez, R. A., Salem, S. M., Anis, R. H., & Hanafy, A. S. (2022) · Clinical and Experimental Medicine · doi:10.1007/s10238-022-00917-x · Cited by 45
“Reduction in butyrate-producing bacteria as Fecalbacterium Prausnitzii, which is an energy source for intestinal epithelial cells, combined with an increase in sulfate-reducing bacteria (SRB) [11], which metabolize sulfate into hydrogen sulfide, thus blocking butyrate utilization and inhibiting pathogen phagocytosis,…”
BackgroundUrobiome: In Sickness and in Health
Wojciuk, B., Salabura, A., Grygorcewicz, B., Kędzierska-Kapuza, K., Ciechanowski, K., & Dołęgowska, B. (2019) · Microorganisms · doi:10.3390/microorganisms7110548 · Cited by 42
“Furthermore, it has been found in other seemingly distant pathologies, such as mental disorders [7,8].”
BackgroundLiu, X., Zhang, Y., Li, W., Yin, J., Zhang, B., Wang, J., & Wang, S. (2022) · Food Research International · doi:10.1016/j.foodres.2022.112072 · Cited by 46
Huang, X., Hu, J., Zhang, H., Li, J., Zhu, X., Liu, Y., Liang, Y., & Mei, Y. (2023) · Microbiology Spectrum · doi:10.1128/spectrum.04370-22 · Cited by 47
“decades as a factor in UC pathogenesis (4).”
BackgroundMa, B., Barathan, M., Ng, M. H., & Law, J. X. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26073148 · Cited by 44
“One of the hallmarks of CD is alteration of the gut microbiota, often referred to as dysbiosis [106].”
Probiotic-Induced Tolerogenic Dendritic Cells: A Novel Therapy for Inflammatory Bowel Disease?
Ghavami, S. B., Aghdaei, H. A., Sorrentino, D. R., Shahrokh, S., Farmani, M., Ashrafian, F., Dore, M. P., Raftar, S. K. A., Khoramjoo, S. M., & Zali, M. R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22158274 · Cited by 41
“The causes of IBDs are still unknown, but—among others—gut microbiota have been shown to play a critical role in the immune alteration in IBD patients [3].”
BackgroundSkoufou, M., Tsigalou, C., Vradelis, S., & Bezirtzoglou, E. (2024) · Microorganisms · doi:10.3390/microorganisms12010194 · Cited by 49
“This chronic inflammation can disrupt the balance that is decrease in the variation of microorganisms and increase in specific bacterial taxa [145].”
BackgroundExploring the Gut Microbiome’s Role in Inflammatory Bowel Disease: Insights and Interventions
Gyriki, D., Nikolaidis, C. G., Stavropoulou, E., Bezirtzoglou, I., Tsigalou, C., Vradelis, S., & Bezirtzoglou, E. (2024) · Journal of Personalized Medicine · doi:10.3390/jpm14050507 · Cited by 43
“Examples of such interventions include probiotics, prebiotics, symbiotics, postbiotics, and faecal microbiota transplantation [65].”
BackgroundHong, D., Kim, H. K., Yang, W., Yoon, C., Kim, M., Yang, C., & Yoon, S. (2024) · Communications Biology · doi:10.1038/s42003-024-06409-w · Cited by 47
Natural Products for the Prevention and Control of the COVID-19 Pandemic: Sustainable Bioresources
Singla, R. K., He, X., Chopra, H., Tsagkaris, C., Shen, L., Kamal, M. A., & Shen, B. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.758159 · Cited by 45
“A dysbiotic microbiome has been detected in several diseases from inflammatory bowel diseases (IBDs) to cardiovascular diseases and depression (Tang et al., 2017; Khan et al., 2019).”
BackgroundKouhounde, S. H. S., Adéoti, K., Mounir, M., Giusti, A., Refinetti, P., Otu, A. A., Effa, E., Ebenso, B., Adetimirin, V. O., Mercader, J., et al. (2022) · Microorganisms · doi:10.3390/microorganisms10091700 · Cited by 49
Tarapatzi, G., Filidou, E., Kandilogiannakis, L., Spathakis, M., Gaitanidou, M., Arvanitidis, K. I., Drygiannakis, I., Valatas, V., Kotzampassi, K. E., Manolopoulos, V. G., et al. (2022) · Pharmaceuticals · doi:10.3390/ph15101293 · Cited by 41
Mańkowska-Wierzbicka, D., Stelmach-Mardas, M., Gabryel, M., Tomczak, H., Skrzypczak-Zielińska, M., Zakerska-Banaszak, O., Sowińska, A., Mahadea, D., Baturo, A., Wolko, Ł., et al. (2020) · Biomedicines · doi:10.3390/biomedicines8080268 · Cited by 39
Hu, J., Mei, Y., Zhang, H., Li, J., Zhang, M., Li, Y., Yang, W., Liu, Y., & Liang, Y. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.130959 · Cited by 45
Kan, J., Chen, C., Huo, T., Xie, W., Hui, Y., Liu, J., & Jin, C. (2020) · Journal of Functional Foods · doi:10.1016/j.jff.2020.104082 · Cited by 41
Control of Gut Inflammation by Modulation of Purinergic Signaling
Vuerich, M., Mukherjee, S., Robson, S. C., & Longhi, M. S. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01882 · Cited by 40
“IBD is a chronic inflammatory condition of the gastrointestinal tract associated with altered gut microbial composition, disrupted mucosa structure and systemic biochemical alterations (5, 6).”
BackgroundResultSchizophrenia and risk of new-onset inflammatory bowel disease: A nationwide longitudinal study
Sung, K., Zhang, B., Wang, H. E., Bai, Y., Tsai, S., Su, T., Chen, T., Hou, M., Lu, C., Wang, Y., et al. (2022) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16856 · Cited by 38
Self-citationLv, H., Jia, H., Cai, W., Cao, R., Xue, C., & Dong, N. (2022) · Journal of the Science of Food and Agriculture · doi:10.1002/jsfa.12326 · Cited by 38
Paediatric Inflammatory Bowel Disease and its Relationship with the Microbiome
Fitzgerald, R. S., Sanderson, I. R., & Claesson, M. J. (2021) · Microbial Ecology · doi:10.1007/s00248-021-01697-9 · Cited by 42
Extraintestinal Manifestations of Inflammatory Bowel Disease
Malik, T. F., & Aurelio, D. M. (2021) · StatPearls · Cited by 38
Gut dysbiosis and clinical phases of pancolitis in patients with ulcerative colitis
Maldonado‐Arriaga, B., Sandoval-Jiménez, S., Rodríguez‐Silverio, J., Alcaráz‐Estrada, S. L., Cortés‐Espinosa, T., de Vaca, R. P., Licona‐Cassani, C., Gámez-Valdez, J. S., Shaw, J. G., Mondragón‐Terán, P., et al. (2021) · MicrobiologyOpen · doi:10.1002/mbo3.1181 · Cited by 46
“Particularly, the findings of a reduced proportion of the genera Faecalibacterium and Roseburia in active pancolitis, and their restoration in remission pancolitis, has also been observed in previous reports (Khan et al., 2019; Man et al., 2011; Palmela et al., 2018; Vigsnæs et al., 2012).”
ResultGut microbiota, an emergent target to shape the efficiency of cancer therapy
Kouidhi, S., Zidi, O., Belkhiria, Z., Raïs, H., Ayadi, A., Ayed, F. B., Mosbah, A., Cherif, A., & Gaaied, A. B. A. E. (2023) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2023.00132 · Cited by 39
“Recently, the literature has linked dysbiosis to the development of several diseases such as obesity and metabolic disorders [29], type 2 diabetes [30], inflammatory bowel diseases [31], and cancers [32].”
BackgroundRevolutionizing Gastrointestinal Disorder Management: Cutting-Edge Advances and Future Prospects
Suri, C., Pande, B., Sahu, T. A., Sahithi, L. S., & Verma, H. K. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13133977 · Cited by 42
“As the field of microbiota-based interventions and FMT continues to evolve, there is an increasing recognition of their potential role in the management of IBD [91].”
BackgroundTherapeutic Advances in Diabetes, Autoimmune, and Neurological Diseases
Liu, J., Ting, J. P., Al-Azzam, S., Ding, Y., & Afshar, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22062805 · Cited by 40
Dynamic modulation of spleen germinal center reactions by gut bacteria during Plasmodium infection
Mandal, R. K., Denny, J. E., Namazzi, R., Opoka, R. O., Datta, D., John, C. C., & Schmidt, N. W. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109094 · Cited by 37
Kaur, S., Thukral, S. K., Kaur, P., & Samota, M. K. (2021) · Future Foods · doi:10.1016/j.fufo.2021.100043 · Cited by 41
Antimicrobial peptide production in response to gut microbiota imbalance
Cardoso, M. H. E. S., Meneguetti, B. T., Oliveira-Júnior, N. G., Macedo, M. L. R., & Franco, O. L. (2022) · Peptides · doi:10.1016/j.peptides.2022.170865 · Cited by 40
Pi, Y., Zhang, X., Wu, Y., Wang, Z., Bai, Y., Liu, X., Han, D., Zhao, J., Tobin, I., Zhao, J., et al. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.02979-22 · Cited by 39
Self-citationContext-Dependent Regulation of Type17 Immunity by Microbiota at the Intestinal Barrier
Akuzum, B., & Lee, J. (2022) · Immune Network · doi:10.4110/in.2022.22.e46 · Cited by 37
“(143,145) Clostridium clusters (IV and IXV) Decreased in IBD Increase the number and function of colonic Tregs.”
BackgroundAmmer‐Herrmenau, C., Pfisterer, N., van den Berg, T., Gavrilova, I., Amanzada, A., Singh, S. K., Khalil, A., Alili, R., Belda, E., Clément, K., et al. (2021) · mSystems · doi:10.1128/msystems.00750-21 · Cited by 37
Gut Microbiota, Macrophages and Diet: An Intriguing New Triangle in Intestinal Fibrosis
Amamou, A., O’Mahony, C., Leboutte, M., Savoye, G., Ghosh, S., & Marion‐Letellier, R. (2022) · Microorganisms · doi:10.3390/microorganisms10030490 · Cited by 36
The gut microbes in inflammatory bowel disease: Future novel target option for pharmacotherapy
Yuan, S., Wang, K.-S., Meng, H., Hou, X.-T., Xue, J.-C., Liu, B., Cheng, W., Li, J., Zhang, H., Nan, J., et al. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114893 · Cited by 37
Gao, B., Huang, X., Fu, J., Chen, L., Deng, Z., Wang, S.-H., Zhu, Y., Xu, C., Zhang, Y., Zhang, M., et al. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03346-6 · Cited by 41
“During IBD, an increased Firmicutes/Bacteroidota ratio is often observed, which may indicate the therapeutic efficacy [39].”
K-da, S., Peerakietkhajorn, S., Siringoringo, B., Muangnil, P., Wichienchot, S., & Khuituan, P. (2020) · Journal of Functional Foods · doi:10.1016/j.jff.2020.104021 · Cited by 38
Treatment of murine colitis by Saccharomyces boulardii secreting atrial natriuretic peptide
Liu, C., Chang, J.-H., Chang, Y.-C., & Mou, Y. (2020) · Journal of Molecular Medicine · doi:10.1007/s00109-020-01987-8 · Cited by 35
Manipulating effects of fruits and vegetables on gut microbiota – a critical review
Luo, J., Xian, L., Bordiga, M., Brennan, C. S., & Xu, B. (2020) · International Journal of Food Science & Technology · doi:10.1111/ijfs.14927 · Cited by 40
Lê, A., Mantel, M., Marchix, J., Bodinier, M., Jan, G., & Rolli‐Derkinderen, M. (2022) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00002.2022 · Cited by 38
The gut-immune-brain axis in neurodevelopment and neurological disorders
Park, J. C., & Im, S. (2022) · Microbiome Research Reports · doi:10.20517/mrr.2022.11 · Cited by 38
Yeo, S., Park, H., Seo, E., Kim, J., Kim, B. K., Choi, I. S., & Huh, C. S. (2020) · Microorganisms · doi:10.3390/microorganisms8060845 · Cited by 36
Metadata
- Authors
- Khan, I., Ullah, N., Zha, L., Bai, Y., Khan, A., Zhao, T., Che, T., & Zhang, C.
- Affiliations
- Lanzhou University (CN)
- Gansu Key Laboratory of Functional Genomics and Molecular Diagnosis, Lanzhou 730000, China
- Corresponding author
- Zhang, Chunjiang
- Venue
- Pathogens
- Publisher
- MDPI AG
- Published
- 2019-08-13
- Volume
- 8
- Issue
- 3
- Pages
- 126
- ISSN
- 2076-0817 (ISSN-L)
- PMC
- PMC6789542
- OpenAlex
- W2966933380
- Cited by
- 771
- References
- 267
- Citations by year
- 2026: 43 · 2025: 105 · 2024: 149 · 2023: 134 · 2022: 135 · 2021: 132 · 2020: 66 · 2019: 7
- FWCI
- 7.51
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- Pathogens (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Lanzhou University Institutional Repository (submittedVersion, cc-by-nc-sa)
- Lanzhou University Institutional Repository (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Jiangsu Science and Technology Major Project ((No. BA2016036))
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
- Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
- Keywords
- inflammatory bowel disease, gut microbiota, dysbiosis, Crohn's disease, ulcerative colitis, intestinal inflammation, microbiota-based therapy, probiotics, prebiotics, mouse colitis model, IBD pathogenesis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.